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1. Introduction
The acquired immunodeficiency syndrome (AIDS) caused by the Human immunodeficien‐
cy virus (HIV) is by far the most feared disease by any person on the planet. The root cause
of  this  fear  stems from its  relentless  worldwide spread and the  absence  of  an  effective
therapeutic / preventive modality. Since its discovery in the early 1980s, it has been over three
decades of war between mankind and HIV. All attempts to overcome the virus have so far
been unsuccessful due to the unique features of HIV such as, the abilty to undergo rapid
genetic evolution and to establish latent reservoirs. The higly active anti-retroviral therapy
(HAART) is currently the only available strategy to limit the disease progression. Howev‐
er, the principal flaw in HAART is that it fails to eliminate the infection and warrants life
long therapy. Long term treatment with anti-retroviral drugs has the disadvantage of poor
compliance due to adverse effects and also possesses the risk of selecting resistant mutants.
These reasons justify the need to search for novel therapeutic options superior to convention‐
al anti-viral therapy.
Success stories of the Mississippi baby and the Berlin patient have revolutionized the concepts
of HIV treatment and offered hope that HIV is not invincible. The strategies that have been
developed / being developed against HIV, either affect the virus directly at different phases of
its natural course or enhance the immunity to clear the infection from the body. Novel natural
and synthetic compounds, peptides, DNA and RNA manipulatory techniques are being
explored for their ability to impede the virus. Immune based therapies to accentuate specific
anti-HIV immunity have stemmed from the failures encountered with vaccines. Apart from
this, various alternative therapies are also being sought by patients. This chapter elaborates
the various novel options that are currently being developed for HIV treatment and discusses
their potential uses and impediments.
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2. Why should we look beyond the HAART?
The major problem faced with HAART is that it only controls the infection and never eliminates
it. When used continually on a lifelong basis, the HAART provides an infected individual with
a significant improvement of clinical condition, enhancement of the quality of life and drastic
reduction of circulating viral load. Nevertheless, treatment cessation at any point results in a
rebound viremia, stripping off all the benefits that the patient had enjoyed during therapy.
This could be stated as the inherent flaw in HAART, which exerts its inhibitory effect only
against the actively replicating viruses in circulation and has little or no effect in destroying
the quiescent viruses hidden in the latent cellular and anatomical reservoirs. Due to several
reasons, this proviral reservoir gets activated at a later date proceeding to active viral replica‐
tion and viremia, which can occur unchecked upon discontinuation of HAART [1-4].
Another worrisome aspect of HIV is its ability to undergo rapid genetic evolution as a
consequence of its voracious mutating capacity. For a virus with such a feature, lifelong
therapy with anti-retroviral drugs can be deleterious by itself, as the constant drug pressure
eventually selects the resistant mutant viral populations. Such mutant viruses, resistant to the
currently used anti-retroviral drugs have already emerged and are being disseminated in
various countries across the globe. There is a possibility that these strains may replace the drug
susceptible ones and render the HAART inactive.
Lifelong HAART also faces the practical constraint of continuous patient adherence to the
prescribed regimen and also its discontinuation due to adverse drug effects. Optimistic
predictions of worldwide HIV control using HAART would be just a mirage if the impending
failure of the HAART in the future is not foreseen from the present. In the light of these issues,
any attempt to curtail the HIV pandemic warrants the need for novel anti-retroviral agents
and/or strategies to supplement, if not to supplant the HAART [5].
3. Novel agents and strategies currently being tried against HIV
All of the therapeutic strategies which are either currently available or under experimental
research, involve attacking HIV at any one of the different phases in its infection course.
(Figure-1) All these strategies use one or more of the following principles including adminis‐
tration of active chemical compounds, nanotechnology, DNA manipulation, RNA based
techniques and cellular transplants.
Apart from these therapeutic strategies which directly impede the viral activity, several
immune based therapies are also being developed which intend to enhance the ability of the
immune system to overcome HIV on its own. These strategies also act at one or more points
in the natural course of HIV infection allowing the immune system to suppress and possibly
eliminate HIV [6].
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4. Agents and strategies inhibiting retroviral replication
4.1. Using the HAART for a functional cure
The HAART and the other anti-retroviral agents halt the natural course of HIV infection at the
phase of active viral replication. This section elucidates the newer concepts that propose to
maximize the utility of the existing anti-retroviral agents and also sheds light on novel
compounds and targets which could be exploited for use against HIV.
Figure 1. Natural course of HIV infection and the targeting points of therapeutic strategies
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The scope of the HAART to achieve a ‘functional cure’ is being studied extensively. Functional
cure is said to be achieved when the infected individual treated aggressively with HAART
early in the course of infection, does not develop rebound viremia on cessation of therapy for
several months [7]. This concept had stemmed from the story of the Mississippi baby, where
a mother seropositive for HIV-1 gave birth to an infant who was also found to be infected.
Anti-retroviral therapy was initiated to the baby at 30 hours of birth and was continued till 18
months of age after which the therapy was discontinued. Surprisingly at 30 months of age, the
child was tested negative for plasma HIV-1 RNA, proviral DNA in peripheral-blood mono‐
nuclear cells and serum HIV-1 antibodies [8].
In an attempt to replicate the observations of the Mississippi baby, the VISCONTI study
conducted in France has effectively achieved a functional cure in a cohort of 14 adults who
currently are free of viremia even after several years of interruption of anti-retroviral therapy
[9]. Likewise, functional cure has been reported in an elderly German patient who had
deliberately interrupted treatment after five years and has controlled rebound viremia for nine
years after the cessation of treatment [10].
The reason hypothesized behind functional cure is that, early aggressive treatment prevents
the build-up of large latent reservoirs and also reduces the viral load low enough that the
immune system clears off the residual infection without continued use of antiretroviral drugs
[11]. The drawback of this concept is that it necessitates the stoppage of the anti-retroviral
drugs that have helped in the control of viremia. It is not known whether this might result in
a functional cure or cause a rebound viremia. As it would be unethical to stop treatment in an
individual with good viremic control without knowing the correlates of protection, well
designed clinical trials must be conducted prior to implementation of this concept, to obtain
answers to questions of uncertainty such as; what is the time period within which the treatment
should be initiated following infection to favour functional cure? How long should the
treatment be given? When is the ideal time for the interruption of treatment? What are the host
factors involved in protection?
By the time the functional cure concept offered some hope, the occurrence of rebound viremia
in the Mississippi baby smashed all the excitement [12]. It might only be a matter of time before
we know whether the other patients claimed to be functionally cured, progress to viremia or
remain “cured“. Nevertheless, the Mississippi baby and the other studies have hinted that
control of viremia is possible on treatment cessation. Further studies are required to find how
to prolong this drug-free control of viremia.
4.2. Targeted drug delivery to infected cells
To achieve viremic control by anti-retroviral drugs, the patient should also face a plethora of
untoward effects. Drug interactions, synergistic toxicity of combination, frequent dosing and
pill burden are the various adverse effects of the HAART causing a poor compliance. Novel
techniques based on nanotechnology are being developed to overcome the shortcomings of
conventional anti-retroviral drug therapy.
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Targeted drug delivery is the technique that is extensively being applied to accentuate the
beneficial effects and to simultaneously reduce the adverse effects of anti-retroviral drugs. In
the course of infection, HIV gains entry into its target cells by membrane fusion, leaving behind
its envelope and surface glycoproteins on the surface of the infected cells. During active
replication of HIV within the target cells, the infected cells also express these viral glycopro‐
teins synthesized de novo. Active targeting exploits these viral components on the cell surface
to selectively identify the infected cells from the uninfected ones [13]. Active replication of HIV
in vivo, from the point of infection of a CD4 T-cell to release of viral progeny takes an average
of 52 hours for completion [14]. This long generation time of HIV could be effectively utilized
to specifically deliver the anti-retroviral drugs to the infected cells by nanotechnology
methods. This would prevent the dissemination of the viral progeny and reduce the viral load
more effectively than systemically administered anti-retroviral drugs.
The nanoparticles used for targeted drug delivery contain a carrier vessel straddled with a
targeting moiety. The carrier nanoparticles are tiny containers which could be loaded with the
drug of interest and are capable of delivering their cargo into cells upon fusion. Various types
of nanocarriers such as; liposomes, micelles, dendrimers, nanocapsules, nanoemulsions, solid
lipid nanoparticles, polymeric nanoparticles, gold nanoparticles and nanocrystals have been
successfully loaded with one or more known anti-retroviral agents. The active targeting moiety
tagged to the surface of these carriers guides them specifically to the target cells. Recombinant
CD4 molecules or Fab fragments of monoclonal anti-gp120 antibodies which possess high
affinity to HIV envelope glycoproteins are used to actively target the envelope glycoproteins
of HIV present on the surface of the infected CD4 cells [15].
Targeted drug delivery possesses significant advantages over conventional chemotherapy of
which, the most important is the reduction of the adverse effect profile of the anti-retroviral
agents. This is because, the technique concentrates the drug only to the necessary sites and
hence not only it reduces the administered dose, but also avoids the accumulation of drug at
unwanted sites. Besides this, some of the nanoparticles have inherent antiretroviral property
and function synergistically when loaded. This promising technique however, is not devoid
of pitfalls. Nanoparticles face the major problem of opsonization and phagocytic clearance
which occurs almost rapidly following their administration. The process of pegylation which
involves in coating of the nanoparticles with polyethylene glycol overcomes this disadvantage
by making the nanoparticles invisible to immune clearance. However, the fusion kinetics of
these ‘stealth’ nanoparticles is diminished when compared to the non-pegylated ones [16].
Nanocarriers packed with a single drug are more stable and addition of more drugs within
the same nanocarrier makes it more unstable. As monotherapy can accelerate viral resistance,
stable models of multidrug nanocarriers are now being developed [17]. Poor oral bioavaila‐
bility, causation of target cell membrane instability and cytotoxicity, complications in renal
clearance and high production cost are some of the problems that have to be solved before
nanotherapeutics come into effective use [13].
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4.3. Congeners of HAART
The currently available anti-retroviral drugs specifically inhibit a select few steps of HIV
replication such as HIV entry and fusion, reverse transcription, protease action and integration.
Apart from their beneficiary action, the anti-retroviral drugs possess significant adverse
reactions which form the principal reason behind poor compliance and drug withdrawal. With
the advent of pharamacological techniques, congeners of anti-retroviral drugs are being
developed with the aim of minimizing the side effects.
The congeners are molecules of any particular drug class which are engineered to overcome
the pitfalls faced by the existing members of the same drug class. They possess minor structural
modifications that confer one or more favourable properties such as increased biovailability,
increased target site binding affinity or longer half life. By virtue of these properties, the
congeners can be effectively administered at reduced dose and interval and hence possess a
low adverse effect profile. The congeners are subject to clinical trials and would probably fail
or get pass the trial stages to get approved by the United Staes Food and Drug Administration
(FDA) and relevant international bodies. Table-1 summarizes the FDA approved anti-
retroviral dugs for use in the USA and their congeners in the pipeline (updated to October
2014) [18-21].
Stage of HIV replication
inhibited
Anti-retroviral drug class FDA approved agents Congeners
Attachment to CCR5 co-
receptor
Entry inhibitors Maraviroc Cenicriviroc
Vicriviroc
Adaptavir
INCB-9471
PRO-140
Fusion of envelope with cell
membrane
Fusion inhibitors Enfuvirtide Albuvirtide
Reverse transcription Nucleoside / Nucleotide
Reverse Transcriptase
Inhibitors (NRTIs)
Zidovudine
Lamivudine
Stavudine
Didanosine
Emtricitabine
Abacavir
Tenofovir disoproxil
fumarate
Tenofovir alafenamide
Hexadecycloxy propyl
tenofovir
Amdoxovir
Racivir
Festinavir
Elvucitabine
Dexelvucitabine
Non-Nucleoside Reverse
Transcriptase Inhibitors
(NNRTIs)
Nevirapine
Efavirenz
Delaviridine
Etravirine
Rilpivirine
Doravirine
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Stage of HIV replication
inhibited
Anti-retroviral drug class FDA approved agents Congeners
Proteolytic cleavage of
precursor polyprotein into
functional proteins
Protease inhibitors Ritonavir
Nelfinavir
Indinavir
Saquinavir
Atazanavir
Foamprinavir
Tipranavir
Darunavir
-
Integration of viral DNA to
the host cell genome
Integrase inhibitors Raltegravir
Dolutegravir
Elvitegravir
Cabotegravir
Table 1. Anti-retroviral drugs approved by the FDA and their congeners under consideration
4.4. Reducing the pill burden
One of the practical difficulties faced by the multi-drug HAART regimen is the pill burden. It
is glaringly obvious and even scientifically proven that, therapeutic regimens with lesser
number of pills have a better patient adherence [22]. In this context, pills with a fixed dose
combination of more than one anti-retroviral agent are being developed and few have also
been approved by the FDA. Table-2 summarizes the list of combinations approved by the FDA
as of October 2014 [18].
Name of the pill Drugs contained
Epzicom Abacavir and lamivudine
Combivir Zidovudine and lamivudine
Truvada Emtricitabine and tenofovir disoproxil fumarate
Triumec Abacavir, dolutegravir and lamivudine
Trizivir Abacavir, zidovudine and lamivudine
Atripla Efavirenz, emtricitabine and tenofovir disoproxil fumarate
Complera Emtricitabine, rilpivirine and tenofovir disoproxil fumarate
Striblid Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate
Table 2. Fixed dose combinations of anti-retroviral drugs approved by the FDA
Designing a single drug molecule containing the active moieties of two different anti-retroviral
compounds is yet another strategy to reduce the pill burden. These molecules termed ‘port‐
manteau inhibitors’ can exert their anti-retroviral action at two different steps of HIV replica‐
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tion and could thereby reduce an extra pill. Caffeoyl-anilide compounds are evaluated for their
dual action in inhibiting HIV integrase and blocking the CCR5 receptor mediated entry [23].
4.5. Synergistic enhancers of anti-retroviral drug action
Certain compounds such as pharmacokinetic boosters and virostatics, are being evaluated for
their role in potentiating the action of anti-retroviral drugs. The property of pharmacokinetic
boosting is exclusively exploited for protease inhibitors which are metabolized and cleared
from the body by the cytochrome P-450 CYP3A4 enzyme. The effect of protease inhibitors can
be boosted if they are co-administered with compounds that inhibit this enzyme. The protease
inhibitor ritonavir with the propensity to inhibit the cytochrome P-450 CYP3A4 enzyme, when
co-administered with another protease inhibitor not only enhances its bioavailability, but also
acts synergistically to minimize the dosage of both agents [24]. The combination of lopinavir
boosted by ritonavir has been identified to provide maximum benefits with minimal adverse
effects and hence is approved by the FDA and marketed as a fixed dose combination pill under
the name, kaletra. Cobicistat is another unrelated compound which is a potent inhibitor of the
cytochrome P-450 CYP3A4 enzyme without having any inherent anti-retroviral activity. As it
is also capable of boosting the beneficial effects of integrase inhibitors, it is approved for use
along with the fixed combination of elvitegravir, emtricitabine and tenofovir under the trade
name, striblid [18, 25].
Virostatics is an abbreviation for the combination of antiviral (viro) and cytostatic drugs
(static). This combination intends to reduce viremia by inhibiting HIV replication with anti-
retroviral drug and simultaneously reducing the number of the viral target cells (normal CD4
T-cells), using the cytostatic drug. It has been observed that the antiviral drug didanosine
functions synergistically with hydroxyurea, an inhibitor of cellular proliferation to achieve
viral load reduction. As this strategy depends on hydroxyurea induced immunosuppression
for reduction of viremia, more knowledge has to be gained on its practicality, with respect to
didanosine resistant HIV mutants and flare-up of opportunistic infections [26, 27]. The anti-
parasitic / anti-inflammatory drug leflunomide is also found to have similar synergistic effect
to inhibit HIV replication when used along with nucleoside reverse transcriptase inhibitors
[28, 29].
4.6. Novel targets and synthetic molecules to inhibit active retroviral replication
From binding to release, the replication of HIV involves several steps of which, only a few
steps are targeted by the currently available anti-retroviral drugs and their congeners. As the
various sub-cellular and molecular mechanisms of HIV replication are gradually being
unraveled, novel compounds are also being identified to target and inhibit one or more steps
of HIV replication. Most of these are small synthetic molecules identified based on computa‐
tional analysis of their structure and ability to dock at the required site and further screened
for functionality by in vitro bioassays. As the discovery of newer anti-retroviral compounds is
an ongoing process, table-3 summarizes a non-exhaustive list of novel synthetic anti-retroviral
compounds and the phase of HIV replication they inhibit.
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Phase of HIV replication
inhibited
Novel mechanism of action Compound Reference
Entry and fusion Binding to HIV gp 120 and prevention of
its attachment to CD4 receptor
Temsavir and fostemsavir [30]
BMS-488043 [31]
NBD-556 [32]
DCM-205 [33]
Curdlan sulfate [34]
Attachment to the CXCR4 co-receptor
and prevention of HIV envelope fusion
to cell membrane
AMD-11070 [35]
T-22 [36]
KRH-1636 [37]
Uncoating Binding to HIV capsid / cyclophilin-A
and prevention of uncoating by
stabilizing the capsid
Pyrrolopyrazolone derivatives [38]
Quinoxaline derivatives [39]
Destabilisation and dissolution of the
HIV capsid after entry
PF-3450074 (PF74) [40, 41]
I-XW-053 [42]
Reverse transcription and
DNA synthesis
Inhibition of reverse transcription by
novel nucleoside analogues
Adenosine analogs [43]
Inhibition of HIV DNA synthesis and
introduction of lethal mutations
Ribonucleoside analogs [44]
KP-1461 [45]
Reversal of susceptibility in NRTI
resistant mutants
Foscarnet [46]
Transcription Inhibition of viral protein (tat) or
inhibition of the leader sequence of HIV
mRNA (TAR) or inhibition of tat-TAR
interaction to prevent the initiation of
transcription
Quinolone derivatives (HM13N,
NM13)
[47]
Acetylpromazine derivatives [48]
N1-aryl-propane-1,3-diamine [49]
Inhibition of cellular factors responsible
for the elongation of HIV mRNA
Flavopiridol derivatives [50]
Seliciclib [51]
Roscovitine [52]
Iron chelators [53]
Garcinol derivatives (LTK-14) [54]
Ribofuranoside and carbonitrile
derivatives
[55]
Miltefosine [56]
Inhibition of post transcriptional
processing of HIV mRNA
Mycophenolic acid [57]
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Phase of HIV replication
inhibited
Novel mechanism of action Compound Reference
Cytoplasmic export of
HIV mRNA
Inhibition of host proteins involved in
nuclear export of HIV mRNA
PKF050-638 [58]
Translation Inhibition of cellular ATPases involved
in the initiation of HIV mRNA
translation
Rhodanine and triazine
compounds
[59, 60]
Assembly and release Binding to capsid protein and Inhibition
of assembly
benzodiazepines and
benzimidazoles
[61]
Blocking the ion channel function of the
HIV protein vpu
BIT225 [62]
Maturation of progeny
after release
Preventing the release of capsid protein
from its precursor protein in the
progeny virions and thereby rendering
them non-infectious
Bevirimat [63]
Viral DNA integration Inhibition of lens epithelium derived
growth factor protein p75 (LEDGF/p75)
which helps in viral DNA integration
2-(quinolin-3-yl) acetic acid
derivatives
[21]
Chicoric acid derivatives [64]
Enhancing the anti-viral
restriction factors of the
host cell
Inhibition of HIV virion infectivity factor
(vif) to indirectly improve the viral
restriction by APOBEC proteins
RN-18 [65, 66]
VEC-5 [67]
Direct enhancement of APOBEC
proteins
SN-2 [68]
Multiple steps Inhibition of uncoating and assembly Thiourea compounds [69]
Acylhydrazone derivatives [70]
Inhibition of viral entry and
transcription
Aminoglcosides (Neomycin,
netilmicin)
[47]
Direct destruction of free
HIV virions
Cation mediated destruction of HIV
envelope
Ceragenins (CSA-54) [71]
Selective cytolysis of HIV
infected cells
Inhibition of acute viral infection and
activation of apoptotic pathways
specifically in cells infected with HIV
Ciclopirox and deferiprone [72]
Table 3. Novel synthetic anti-retroviral compounds and their mechanism of action
Although most of these compounds have shown potent in vitro anti-retroviral activity, their
in vivo efficacy needs to be evaluated. A few of the listed drug candidates are undergoing
clinical trials and are expected to be available for use in the near future. The concept of using
antiviral compounds for treatment of HIV poses a significant drawback. Unlike other viruses,
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HIV possesses an immense potential to undergo genetic variation and the anti-retroviral agents
rapidly select out resistant mutants. This could be well explained with the experiences faced
with the experimental uncoating inhibitor PF74 and the maturation inhibitor bevirimat. The
action of both these drugs can be nullified by HIV with simple mutations causing amino acid
substitutions and these resistant mutants are expected to emerge rapidly if these drugs get
approved for widespread use [41, 73]. While comparing the length of time and amount of work
required to approve new anti-retroviral molecules acting on viral components, it is almost an
instantaneous process for HIV to develop resistance against the drugs. In this context,
compounds that inhibit the genetically more stable host components to produce anti-retroviral
effects such as the CCR5 / CXCR4 inhibitors hold promise, until the virus finds an alternative
to evade their action.
4.7. Natural derivatives with anti-retroviral property
Apart from the multitude of synthetic anti-retroviral compounds that are being generated
every day, many naturally occurring compounds have also been identified to inhibit HIV [74,
75]. Plants, marine organisms, arthropod venoms and bacteria form the principal sources of
these compounds. Extracts from natural sources are tested in vitro for anti-retroviral activity
and the most active component identified, purified and studied for possible mechanism of
action. Interestingly, some of the natural compounds have been found to perform better than
their synthetic counterparts [73]. Recently, virtual methods are being developed for screening
natural compounds for their anti-retroviral property [76]. If the in vitro effects could be
effectively achieved in vivo, it would not be surprising when some of these compounds soon
make their way across clinical trials and be available for use in the near future. Table-4
summarizes some recent compounds of renewed interest among various naturally occurring
anti-retroviral compounds already identified.
Source Source organism Compound Mechanism of anti-retroviral action Reference
Plants Camellia sinensis (Green
tea)
Epigallocatechin-3-
gallate
Inhibits HIV transcription. Also
degrades the semen-derived enhancer of
virus infection and prevents mucosal
transmission
[77, 78]
Eucalyptus globoidea
(Australian Eucalyptus
tree)
Globoidnan A Inhibits HIV integrase [79]
Betula pubescens
(and several other
plants)
Betulinic acid Prevents the release of capsid protein
from its precursor protein in the
progeny virions and thereby renders
them non-infectious
[73]
Isatis indigotica (Chinese
medicinal plant)
Indirubin-3'-monoximeInhibits host cellular machinery
responsible for HIV transcription
[80]
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Source Source organism Compound Mechanism of anti-retroviral action Reference
Salvia miltiorrhiza
(Chinese medicinal
plant)
Tanshinone II A Inhibits host cellular machinery
responsible for HIV transcription
[81]
Pelargonium sidoides
(German medicinal
plant)
Unidentified
compounds
Inhibits HIV entry [82]
Grapes and berries Resveratrol Inhibits tat-induced HIV transactivation.
Also possess cystostatic effects on CD4
T-cells similar to hydroxyl urea
[83]
Grapefruit juice Unidentified
compounds
Neutralizes the CYP3A4 in the GI tract
and increases the bioavailabity of anti-
retrovirals
[84]
Marine
species
Griffithsia species (Red
algae)
Griffithsin / Grifonin-1 Binds to various HIV surface
components including gp41 and gp120
and inhibits entry
[85, 86]
Corticium simplex
(Sponge)
didehydro-cortistatin
A
Most potent inhibitor of tat-dependent
HIV transcription identified till date
[47, 87]
Fascaplysinopsis reticulata
(Sponge)
Fascaplysin Inhibits host cellular machinery
responsible for HIV transcription. Also
inhibits HIV reverse transcriptase
[88]
Cassiopia Andromeda
(Jelly fish)
Cnidarian proteins Various anti-HIV activities including
inhibition of HIV protease, inhibition of
HIV entry and cytotoxicity of infected
cells
[89, 90]
Galaxura filamentosa
(Red algae)
Litophyton arboreum
(Soft coral)
Bacteria Nostoc ellipsosporum
(Cyanobacterium)
Cyanovirin-N Binds to various HIV surface
components including gp41 and gp120
and inhibits entry
[91]
Scytonema varium
(Cyanobacterium)
Scytovirin [92]
Sorangium cellulosum
(Myxobacterium)
Ratjadone-A Inhibits host proteins involved in
nuclear export of HIV mRNA
[93]
Streptomyces species
(Actinomycete)
Leptomycin-B Inhibits the viral protein rev which helps
in nuclear export of HIV mRNA
[94]
Arthropods Bee venom Melittin Binds to various HIV surface
components and disintegrates the
envelope
[95]
Scorpion venom Kn2-7 Interacts with HIV envelope and inhibits
entry
[96]
Table 4. Anti-retroviral compounds isolated from natural sources
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4.8. Anti-retroviral peptides
Eukaryotic organisms are known to secrete antimicrobial peptides as a part of their innate
immunity, which have a broad spectrum of activity against various pathogenic microbes [97].
These peptides are usually short sequences of 12 - 20 amino acids, but some of them may also
be around 40 amino acids long. Apart from the inherent anti-retroviral peptides produced by
the human body, numerous studies have identified several peptides from natural and
synthetic sources that are capable of inhibiting HIV replication [98]. With the FDA approval
of the fusion inhibitor peptide enfuvirtide, coupled with the growing problem of resistance to
anti-retroviral drugs, much interest is being shown in the development of novel anti-retroviral
peptides. Currently, there are nearly a thousand HIV inhibiting peptides identified and new
members are being added on a daily basis [99].
The anti-retroviral peptides identified till date are predominantly from natural sources ranging
from bacteria to plants to primates. Also a significant number of these peptides are derivatives
of HIV itself, which structurally mimic the viral substrates and competitively inhibit the
various replicatory processes. On the other hand, synthetic production using techniques such
as phage display, offer the scope of combination of related or unrelated peptides to achieve
maximal anti-retroviral effect. Most of the anti-retroviral peptides inhibit one or more of the
phases of HIV replication. Majority of the peptides act extracellularly to inhibit HIV attachment
or its fusion while others inhibit the intracellular phases of replication such as reverse tran‐
scription, transcription and integration. Apart from the direct administration of peptides for
therapy, these agents could also be administered in their complementary DNA form which on
recombination with the host cell genome and subsequent expression, makes the target cell
resilient to HIV infection (subsequently discussed). Certain peptides possess the unique
property of cell penetration and hence being evaluated for their possible role in targeted
nanotechnological and cellular delivery techniques [99, 100].
The advantages of therapeutic peptides include their high specificity for the site of action, rapid
break down into harmless amino acids which are eliminated easily and hence possess less
toxicity and adverse effect profile [98]. However, this rapid breakdown of peptides by the
peptidases could also be a drawback since they could be cleared off before they exert their
action. Currently, synthetic peptides incorporated with D-isomers of amino acids (instead of
the naturally occurring L-isomers) or with added non-peptide moieties, overcome this
drawback and possess extended half life [101]. Peptides are highly antigenic and elicit the
production of antibodies. Hence the extracellular acting peptides face the problem of antibody
mediated clearance. Although the intracellular acting peptides are devoid of the antibody
problem, availability of efficient delivery systems into the cell and degradation by the
intracellular peptidases are the challenges they face. Poor oral bioavailability, inability to cross
biological barriers and high production cost are further problems to be addressed prior to
approval for therapeutic use [100, 102]. The FDA however, has approved enfuvirtide, this
approval has offered hope for the success of other anti-retroviral peptides currently undergo‐
ing clinical trials [103]. With advancements in nanotechnology and cellular delivery systems,
peptide therapy might become a reality for HIV infection in due course of time.
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4.9. RNA based therapeutics
RNA based therapeutic strategies exert their action between the phases of transcription and
translation. Numerous RNA based techniques have been developed which are classified by
their mechanism of action. They include; inhibitors of messenger RNA (mRNA) translation
(antisense oligonucleotides), the agents of RNA interference (RNAi), catalytically active RNA
molecules (ribozymes) and RNAs that bind proteins and other molecular ligands (aptamers)
[104, 105] (Table-5). These techniques can be utilized for the treatment of any viral disease by
engineering specific, complementary inhibitory RNA particles to the viral transcription
components. Among these techniques, RNAi and to a lesser extent antisense oligonucleotides,
have been tried out to inhibit retroviral replication. As these techniques can also target the host
cellular processes, they are being exploited in strategies to increase the resilience of target cells
to HIV infection, which is discussed later [106].
RNAi is an endogenous mechanism which involves the down regulation of mRNA activity
during transcription and post transcription phases using short double stranded RNA (dsRNA)
called micro RNA (miRNA), which are about 20-30bp long. The identification of this regulatory
process has provoked the interest of controlling unwanted viral replication using exogenously
administered specific sequences of short dsRNA. The exogenously administered agents of
RNAi therapy include small interfering RNA (siRNA) and short hairpin RNA (shRNA). These
agents act on the post transcript mRNA and either cause direct sequence specific cleavage
when there is a perfect sequence complementarity match, or lead to translational repression
and degradation of mRNA when the interfering RNA sequence is of limited complimentarity
to the targeted mRNA. As the siRNA get cleared off after their action, their effects are only
transient and need repeated administration similar to agents of chemotherapy. On the other
hand the action of shRNA is similar to gene therapy, as they get expressed on promoters and
cause long term effects. Various viral and non-viral delivery mechanisms and active targeting
strategies have been developed to deliver these active agents into the target cells [107, 108].
Systems employing siRNA and shRNA to target the gene products of tat, rev, nef, env, vif and
pol have been designed and evaluated for efficacy [47, 106]. However, the use of this technol‐
ogy against viral replicatory processess is threatened by the genetic variation exhibited by HIV.
Very simple mutations allow HIV to escape from the action of both siRNA and shRNA [109,
110]. Four possible solutions are being tried to tackle the problem of these escape mutants. The
first attempt is to expand the RNAi technique to simulataneously inhibit multiple HIV mRNA
targets similar to the concept of multidrug use. Recent studies have demonstrated that
concurrent inhibition of HIV mRNA with three different shRNAs can prevent viral escape in
vitro [111, 112]. In the second possible solution, inhibitory RNAs with a complete match to the
most commonly encountered viral escape sequences are being designed. When used along
with the inhibitory RNA of the wild type virus, these could prevent a majority of the mutants
from escape [113]. The third solution involves identifying novel, genetically conserved
sequences of HIV which do not usually undergo mutation. Targeting these stable sites would
favour the success of RNAi [114]. Finally, RNAi techniques are also being designed to restrict
the ‘genetically more stable’ host factors that help in HIV replication (discussed later under
strategies to enhance target cell resilience to HIV infection).
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Apart from the disadvantages posed by the virus per se, RNAi technology has numerous
setbacks. The short lived action of siRNA warrants its repetitive administration thereby
compounding the treatment cost. The overexpression of shRNA can result in cell death and
hence needs strict dose titration. RNA is immunogenic and is rapidly neutralized by antibodies
in circulation, hence effective vectors are needed for the in vivo administration of RNA. Even
after successful intracellular delivery, the administered RNA moieties are easy targets for
degradation by cytoplasmic ribonucleases. Engineered RNA with modifications in sugar
moieties, nucleotides or their backbone are found to possess improved cytoplasmic stability
and are being evaluated for their superiority and efficacy [115].
Due to the numerous setbacks, almost all RNAi techniques that exclusively inhibit the viral
targets have stagnated at the level of pre-clinical testing and none have entered into clinical
trials. A recent technique which involves the simultaneous use of three shRNAs to specifically
inhibit three corresponding targets of HIV, has been found to be safe and effective and is
hopeful to enter phase I trials in the near future [111].
5. Strategies to eliminate latent reservoirs
The ability to integrate its nucleic acids with host cell genome and co-exist in a genetically
quiescent proviral state is one of the distinct features of HIV, which makes eradication of
infection next to impossible. The latent reservoirs of HIV are categorized into two broad groups
namely the cellular and the anatomical reservoir. The cellular reservoir comprises the long
lived resting CD4 T-cells. With an extended lifespan averaging 400 days, these cells bear the
provirus and release the progeny upon activation at a later time [116]. Infection of the cells of
the monocyte-macrophage lineage and subsequent compartmentalization of these infected
cells into various organs / tissues such as the reticulo-endothelial system, lymph nodes, gastro-
intestinal tract, brain and lungs, lead to the formation of anatomical reservoirs. Within the
macrophages of these anatomical reservoirs, the HIV either remains quiescent inside the
chronically infected cells or maintains a continuous low level replication [117]. Thus, the
reservoirs act as Trojan horses spilling the progeny virions into circulation at periodic intervals.
Although the mechanisms involved in proviral repression are gradually being unraveled,
specific factors / agents reactivating the viral replication are yet to be clearly identified.
Although early aggressive treatment helps in achieving a functional cure by limiting the
reservoir formation, it does not offer a solution to the already established reservoirs. The new
strategies and techniques that are being developed for eradicating the established viral
reservoirs are subsequently discussed.
5.1. Targeted drug delivery to the reservoirs
Apart from attempts to limit viral replication in actively infected CD4 T-cells, nanotechnology
methods are widely studied for the elimination of the latent viral reservoirs. Strategies include
passive and active targeting and the use of surface moieties which enhance the penetration of
biological barriers by the nanoparticles.
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Upon systemic administration, most of the nanoparticles are instantaneously opsonized with
plasma proteins and rapidly cleared off from circulation by the phagocytosis. The macro‐
phages of the reticulo-endothelial system are the principal cells which are involved in the
degradation and clearance of the nanoparticles [118]. This forms the basis of passive targeting
which aims at achieving high concentrations of anti-retroviral agents in the reticulo-endothe‐
lial reservoir as a consequence of phagocytosis of the drug loaded nanoparticles. Studies have
demonstrated the achievement of higher drug concentrations in the reticulo-endothelial cells
following the administration of liposomes, nanocapsules or polymeric nanoparticles loaded
with anti-retroviral drugs [119]. Likewise, passive targeting of the lymphatic reservoir can be
achieved by incorporation of the nanoparticles with lipids such as phosphatidylcholine and
cholesterol or by surface coating of the nanocarriers with polyethylene glycol [120, 121].
Apart from passive targeting, specific drug delivery to the anatomical reservoirs can be
accomplished by active targeting strategies. Nanocarriers tagged on their surface with
galactose or mannose residues or anti-HLA-DR monoclonal antibodies, effectively localize in
the reticulo-endothelial system which have abundant receptors for these ligands such as the
galactose and lectin receptors and the HLA-DR determinant of MHC-II respectively. Active
targeting of the cellular reservoirs is based on the aforementioned principle of employing
nanocarriers with homing ligands to viral components on infected cell surface. The infected
resting CD4 T-cells containing HIV envelope glycoproteins on their surface attract the drug
loaded nanoparticles coated with recombinant CD4 molecules or Fab fragments of monoclonal
anti-gp120 antibodies [13].
Nanotechnology also offers a solution for the problem of poor drug penetration in certain
anatomical sites. One such anatomical reservoir is the brain, where the infected microglial
cells rest safely with the protection conferred by the blood brain barrier against the system‐
ically  administered anti-retroviral  agents.  The blood brain barrier  functions  not  only by
preventing the permeation of the circulating anti-retroviral compounds into the brain tissue,
but also by efflux of a considerable portion of the compounds that have managed to cross
through. With the ability to increase the crossing and reduce the efflux of drugs, nanotechnol‐
ogy methods help in reservoir elimination by overcoming the privilege offered by the blood
brain barrier [122].
Nanotechnology methods that increase the drug transport across the blood brain barrier
function by mimicry of natural substrates, utilization of cell penetrating peptides or by active
targeting of molecules of abundance in neuronal vasculature with suitable surface ligands. The
non-ionic surfactant ‘polysorbate-80’ has found to be an effective enhancer of drug delivery
to the brain using the principle of substrate mimicry. Upon systemic administration, the drug
loaded nanoparticles coated with polysorbate-80 adsorb various apolipoproteins in circulation
to form a complex that mimics lipoproteins. Presuming them as natural substrates, the blood
brain barrier permits the entry of these complexes by receptor mediated transcytosis resulting
in delivery of the drug to the brain tissue [123]. Nanoparticles coated with cell penetrating
peptides such as the HIV-1 tat peptide has shown enhanced efficacy in crossing the blood brain
barrier. As the microvasculature of the brain is rich in receptors such as transferring receptor,
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low-density lipoprotein receptor and β2 receptors, their respective ligands such as transferrin,
apolipoprotein-E and β2 agonists are considered possible candidates for active targeting.
The use of nanotechnology for reservoir elimination poses some peculiar problems in addition
to other drawbacks mentioned earlier. The effectiveness of nanotechniques that rely on anti-
retroviral drugs to eliminate the reservoir is questionable as these agents are lethal to the virus
only during active replication and do not affect the inactive provirus. The final clearance of
the nanoparticles from the anatomical sites, especially from the brain is not clearly known and
accumulation overtime with repeated doses can possibly lead to neurotoxicity. Acquisition of
more knowledge through carefully designed clinical trials is needed so that the potential of
this technology could be put into adequate use [122].
5.2. The ‘shock and kill’ strategy
Considered as the ‘holy grail’ of HIV eradication research, this strategy aims at depletion of
the latent reservoirs by widespread activation of the provirus using ‘shocking agents’ and
subsequent killing of the actively replicating virions. Reactivation of the quiescent viral genes
can be achieved either by inactivating the repressing factors and/or by activating the tran‐
scription factors [13].
Deacetylation and methylation of histones and DNA methylation are the few processes that
have been identified to favour the proviral repression and hence the inhibitors of these
processes are considered as attractive candidates for shocking agents. Inhibitors of the histone
deacetylase group of enzymes; valproate and vorinostat have been tried out for viral reacti‐
vation with limited success [124]. Congeners of vorinostat such as givinostat, belinostat,
panobinostat and droxinostat and other novel histone deacetylase inhibiting compounds such
as oxamflatin, romidepsin are being evaluated for their efficacy in reactivating viral replication.
Histone methyltransferase inhibitor chaetocin and DNA methyltransferase inhibitors azacy‐
tidine and decitabine are also being assessed for their efficacy as shocking agents [125].
Provirus could also be drawn into active replication by making the intracellular milleu
conducive for transcription [126, 127]. This could be achieved by activating the transcription
factors such as the NF-κB and transcription elongation factor- b. Initial studies that employed
NF-κB activators such as interleukin-2 and monoclonal anti-CD3 antibodies failed to relieve
the provirus from repression. This led to the identification of a gatekeeper kinase which has
to be concurrently activated along with NF-κB to facilitate viral replication. Other compounds
such as prostratin and bryostatin-1 are also being evaluated for efficacy in the activation of
NF-κB pathways [128]. Activators of elongation factor-b such as hexamethylene bisacetam‐
mide, disulfiram and certain quinolones are being evaluated as shocking agents. Apart from
these, interleukin-7, agonists of Toll like receptor-9 and novel syenthetic molecules have been
identified to activate viral replication in the latent reservoirs [125, 129]. All of these transcrip‐
tion activators are being assessed for stand-alone use or for use in combination with inhibitors
of proviral repression.
None of the agents of this attractive strategy has provided satisfactory results so far. The dosing
and combinations have to be worked out to extract maximum effects out of these shocking
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agents. As most of the shocking agents are related to anti-cancer drugs, they are likely to have
a significant adverse effect profile. The activators of the NF-κB pathway are notorious for
triggering a plethora of cytokines and can cause a fatal cytokine storm if administered at higher
concentrations. Another important drawback is that, even if an efficient shocking agent is
identified, killing of the actively replicating virions depends on anti-retroviral drugs which
are expected to lose their efficacy in the future due to the evolution and dissemination of
resistant viral population. Nevertheless, this strategy has immense potential in eradicating
viral reservoirs if the various setbacks are addressed over time [130].
Apart from the trial of different compounds, techniques of gene therapy have also been tried
out to activate viral reservoirs with limited success. Herpes virus and lentiviral vectors loaded
with genes coding for key viral proteins involved in replication were found to induce repli‐
cation and release of the provirus from the latent CD4 T-cells [131]. Problems with in vivo
administration, lack of specificity in targeting the cellular reservoir, low frequency of recom‐
bination are the various setbacks which have withheld the progress of this technology in
reservoir elimination [132].
5.3. Selective cytolysis without viral reactivation
Another interesting finding pertaining to reservoir eradication is the property of the gold
complex drug ‘auranofin’ to selectively destroy the retroviral cellular reservoir. Although
developed and used as an anti-rheumatic agent, the unique ‘anti-memory T-cell effect’ of
auranofin has kindled interest in its possible role against HIV. Auranofin exerts its cytocidal
action by inducing intracellular oxidative stress. The memory T-cells with low antioxidant
defenses are highly vulnerable to the oxidative stress induced by auranofin and perish along
with the integrated provirus. Combination of auranofin and buthionine sulfoximine, an
inhibitor of glutathione synthesis is found to act synergistically by causing further imbalance
in the redox pathways [133].
Auranofin has shown promising results in studies utilizing the simian AIDS model. Simian
immunodeficiency virus (SIV) infected macaques, treated with a combination regimen of
auranofin, buthionine and HAART have not only shown a prolonged post treatment drug free
control of viremia but also developed enhanced cell mediated immunity with SIV specific
cytotoxic CD8 T-cells following treatment suspension [134, 135]. However, well designed
human clinical trials are required to know more about this anti-HIV reservoir compound
before its flamboyance could be translated to practicality.
5.4. Repression of latency
With the mechanism exactly opposite to the shock and kill strategy, this strategy aims at
achieving viremic control by keeping the viral reservoirs continually in the inactive state. As
mentioned under the shock and kill strategy, concurrent activation of the gatekeeper kinase
and NF-κB favours reactivation of the provirus. The compound Jun N-terminal protein kinase
inhibitor-5 which is a potent inhibitor of the gatekeeper kinase strongly prevents viral reactiva‐
tion even upon strong stimulation of the NF-κB pathway under in vitro conditions. Inhibitors
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of the NF-κB pathway such as aloisine A and roscovitine also inhibit HIV reactivation to a lesser
extent [128]. Various other molecules such as C-terminal truncated STAT5, Staf 50, prothymo‐
sin α, thioredoxin reductase, glucosamine and OKT-18 zinc finger protein have been identi‐
fied to prolong the proviral repression. As the HIV protein ‘Tat’ activates proviral transcription
after getting itself activated by acetylation, molecules that could specifically inhibit host cell
acetylases which, eventually subdues the activity of the Tat peptide, can serve as attractive
candidates for continuing viral repression [136]. Also, molecules that enhance the activity of
the histone deacetylase if identified, could serve as suitable agents for this strategy [137].
5.5. Genome editing
Genome editing techniques confer the possibility of excising out specific genetic sequences
from the whole genome. This novel concept is currently being used for research involving in
eukaryotic genome manipulation to produce gene knockout animals. The ability of this
technology to specifically excise the integrated provirus from the genome of the latent reservoir
cells is being evaluated.
Three different genome editing systems are currently available such as the zinc finger nucle‐
ase (ZFN) system, the transcription activator like-effector nucleases (TALEN) system and the
clustered regularly interspaced short palindromic repeat (CRISPR) with CRISPR-associated
protein-9 (Cas9) known as the CRISPR/Cas9 system (Table-5). Of the three systems, the ZFN
and the CRISPR/Cas9 system are being tried in the genome editing of the latent reservoir cells.
In vitro  studies employing the CRISPR/Cas9 system have demonstrated the ability of the
technique to remove the HIV internal genes and suppress proviral reactivation in T cells [138].
Alternatively, studies employing the ZFN system have demonstrated the ability of the technique
to excise the full length HIV proviral DNA from the infected human T cell genome [139].
This advanced technology also has its own drawbacks. The efficacy of genome editing
strategies observed with different in vitro studies is about 30% though research work is still
ongoing, addressing the challenges and improving on the efficacy. Suitable transport systems
are yet to be developed for in vivo delivery of the editing machinery to the viral reservoir cells.
All genetic editing systems have a certain proportion of ‘off-target activity’ where they excise
out genes unrelated to the targeted site. As this can result in undesired gene modification
events, the genome editing systems must be made more specific before its utilization for anti-
HIV treatment [140].
6. Strategies enhancing target cell resilience to HIV infection
6.1. Replacement therapy
The discovery of HIV cure by replacement therapy happened by chance from the observations
made on Timothy Brown, widely referred as the ‘Berlin patient’. The patient was seropositive
for HIV and had undergone an allogenic bone marrow transplant on developing acute
myelogenous leukemia. Incidentally, the transplanted donor stem cells carried a homozygous
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CCR5Δ32 deletion and produced T-cells with a truncated chemokine receptor CCR5 conferring
resistance to infection with CCR5 utilizing virus. The patient had discontinued HAART after
the transplant yet has had no detectable viremia for over five years [141]. The experiences with
the Berlin patient, introduced the concept of ‘sterilizing cure’ which essentially comprises of
eradicating all replication competent viruses from the body including the ones inside the latent
reservoirs.
Replacement with resilient target cells alone does not suffice to achieve a sterilizing cure. As
seen with the Berlin patient, the replacement therapy must be preceded by eradication of latent
reservoirs. This has been effectively achieved in the Berlin patient by the myelo-ablative
procedures prior to bone marrow transplant and continued by the graft versus host disease
which occurred following the transplant [142].
Attempts to replicate the cure of the Berlin patient have not been successful so far. A similar
treatment provided for two adults in Boston resulted in a brief period of aviremic state,
subsequently followed by rebound viremia in both the patients. A few reasons have been
postulated for the failure of sterilizing cure in the Boston patients. The first reason being, the
initial myelo-ablative procedure was milder than that which was given to the Berlin patient
and hence would have not effectively destroyed the viral reservoirs. Also, the donor cells
transplanted to the Boston patients carried a heterozygous CCRΔ32 deletion which might
allow HIV infection, when compared to the more resilient homozygous mutant cells trans‐
planted to the Berlin patient [143].
Although well substantiated, the concept of sterilizing cure still has many lacunae. The exact
correlates of protection involved in pre-transplant reservoir ablation, establishment of a graft
versus host disease and homozygous versus heterozygous CCR5Δ32 deletion are yet to be
identified. It has been observed that CCR5Δ32 deletion is associated with increased suscepti‐
bility to infections with West Nile virus. There may be other serious adverse effects which are
to be identified before using defective CCR5 as replacement therapy for HIV infection. Another
thought provoking issue is the ability of defective CCR5 in protecting infections caused by
CXCR4 tropic viruses [144].
Apart from the above mentioned hurdles, the major setback which could limit the reality of
this strategy is the availability of matched donors with the required mutation. Autologous
bone marrow transplant has been considered to overcome these stringent requirements of
allogenic transplants. Transplants of uninfected haematopoietic stem cells harvested earlier
from the same person and made resilient to HIV infection by in vitro genetic modification
(discussed below) do not confer as much protection as their allogenic counterparts. The poor
performance of autologous transplants is attributed to the lack of the ‘allo-effect’ in clearing
the infected reservoirs by establishing a graft versus host disease [145]. Hence it has to be borne
in mind that replacement with resilient target cells is not a stand-alone strategy and must be
compulsorily preceded by reservoir eradication procedures, in order to achieve an effective
sterilizing cure.
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6.2. DNA manipulation
Techniques of DNA manipulation have immense potential and offer a wide scope in tackling
HIV. Apart from their use in peptide delivery and in the shock and kill and the genome editing
strategies for reservoir elimination, the different techniques of genetic manipulation can be
exploited to confer resilience to the natural target cells against HIV infection. DNA manipu‐
latory techniques can confer CD4 T-cells with resilience to HIV infection by either modification
of the natural cellular components which are utilized by HIV or by the administration of
engineered genetic material which get expressed to produce HIV inhibitory peptides. The
techniques utilized for this purpose include gene therapy and genome editing.
Although the term ‘gene therapy’ is interchangeably used to denote all the DNA and RNA
based techniques, this much earlier developed technique actually involves the delivery of
specific genetic elements to the target cells by a suitable vector. This is followed by homologous
recombination of the transferred genetic element with the recipient cell genome and its
eventual participation in transcription and translation to express the desired phenotype.
However attractive it may be, the success of this technique depends on the effective recombi‐
nation of the foreign gene with the target cell genome. Low frequency of recombination is the
principal drawback faced with this technology [146].
The more recent gene editing techniques as mentioned earlier, comprises excising specific
portions of genetic material from the target cell genome. The principle of this technology makes
it a good strategy for reservoir elimination as it can cut off the unwanted proviral genes without
any subsequent untoward effect. Although when used for host cell genetic manipulation, the
success of these techniques relies on the identification of suitable sub-cellular targets, which
on manipulation cause significant impairment of HIV replication without affecting the normal
cellular function. These novel techniques are found to have a higher success rate than other
dated techniques of gene therapy [140].
Though the functional mechanism differ in the techniques, they still have several processes in
common. Firstly, both techniques require an effective carrier-delivery system called vectors
which can deposit the genetic elements / editing machinery specifically to the cells that are to
be modified. Various viral vectors utilizing adenovirus, baculovirus, canary pox virus or
lentivrus have been developed for this purpose. In vivo use of viral vectors face the problem
of antibody mediated clearance. To overcome this challenge, non viral vectors based on
nanoparticles like dendrimers are being developed. Cell electroporation is yet another
technique that has been developed for the in vitro delivery of nucleic acids into target cells
[147]. The second common feature is that, both the techniques can be developed for either in
vitro or in vivo use. The in vitro methods involve in harvesting of the cells of interest, genetic
modification in laboratory conditions followed by transfusion of the modified cells to the
recipient, while the in vivo methods rely on vector mediated delivery by active targeting of the
cells of interest. Another feature of the genetic manipulation procedures is that they could be
performed on either mature cells or stem cells. Modification of mature CD4 T-cells confers
protection only during their life span and warrant the need for repetitive transfusions over
time. On the other hand, genetically modified stem cells such as the CD34+ haematopoietic
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stem cells can be effective with a single transplantation as exemplified with replacement
therapy [148].
Both techniques attempt to make the target cells resilient to HIV infection by either modifying
the cell surface components required for HIV entry or by altering the intracellular contents
which are utilized by the virus during replication, or a combination of both. Strategies involved
in limiting viral entry by surface component modification possess certain remarkable advan‐
tages. It has been detected that among all HIV related cell death events, over 95% are caused
by apoptosis initiated by the cells immediately after viral entry [149]. Hence, the target cells
can be saved from committing ‘suicide’ if they are made impervious to viral entry.
With the serendipitous discovery of its curative effects in the Berlin patient, CCR5 which acts
as the co-receptor for HIV entry is the most sought-after target for genetic modification. A
homozygous deletion of a specific 32 base pair sequence from the CCR5 gene confers complete
protection, while a heterozygous deletion of the same nucleic acids confers partial protection
from HIV entry, without causing any glaring change in the CD4 T-cell function. All the three
systems of gene editing namely the ZFN, the TALEN and the CRISPR/Cas9 system are being
evaluated for this purpose and are found to have nearly 50% efficacy in disrupting CCR5 in
mature CD4 T-cells and around 25% efficacy in adult haematopoietic stem cells. In this regard,
it is intriguing to use induced pluripotent stem (iPS) cells to introduce delta32-like mutation
and test their viral resistance. In vitro studies of CXCR4 disruption has also shown promising
results but this might not serve the purpose in vivo, as the deletion is expected to cause
functional derangement.[140]. Yet another instance of gene therapy under human trials is the
SB-728-T, a zinc finger DNA-binding transcription factor. It binds to the DNA of target cells
and disrupts the gene responsible for CCR5 co-receptor production [150]. Apart from the ones
mentioned here, there are numerous other techniques of DNA manipulation, RNA based and
peptide based techniques being tried to harness the potential of CCR5 alteration in curtailing
HIV infection (Table 5).
The target cells can also be made resistant to HIV infection by increasing the expression of
intracellular factors that restrict the viral replication process. TRIM5α, APOBEC3G and
tetherin are the well known restriction factors of HIV infection. TRIM5α is a cytoplasmic
protein which inhibits HIV by binding with the incoming capsid and preventing further the
process of replication. The APOBEC3 family of mRNA editing proteins, especially the
APOBEC3G inhibits HIV replication by introducing lethal mutations during reverse tran‐
scription. Tetherin is another host cellular protein involved in HIV restriction by preventing
the release of viral progeny from the infected cell.[151] As the vif and vpu proteins of the virus
neutralize the effect of APOBEC3G and tetherin respectively, they can be made resistant to
their respective viral proteins by introducing point mutations. Single amino acid substitution,
D128K in APOBEC3G and T45I in tetherin makes them overcome the viral factors vif and vpu
respectively. Gene therapy techniques to increase the expression of TRIM5α and mutated
APOBEC3G and tetherin in CD4 T-cells are known to enhance their resilience to HIV infection.
Mov 10 and CPSF6 are the newer restriction factors that are being considered for development
in this strategy [106, 152]. Recently, the interferon inducible family of proteins called the
myxovirus resistance proteins (Mxs) have been identified as potent restriction factors which
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act by inhibiting HIV uncoating [153]. Also, TSG-101 the intracellular protein derivative of
tumor susceptibility gene has been identified to inhibit the HIV protein p6 thereby blocking
viral budding and release [154]. These proteins could possibly serve as candidates for anti-
retroviral gene therapy.
Administration and expression of extraneous genetic material can also confer resistance to the
target cells against HIV. Much of recent interest is towards the surface modification using the
synthetic peptide ‘C46’. When expressed on the CD4 T-cell surface, this peptide binds with
gp41 of the approaching virions and prevents envelope fusion. Stable expression of C46 can
be achieved on CD4 T-cells following delivery of the corresponding gene using retroviral
vectors. As the cells made resilient by CCR5 alteration alone remain vulnerable to CXCR4
tropic viruses and the reverse also holds good, C46 can be effectively used to inhibit infection
with both of the viral strains [152]. Extraneously administered genetic material coding for
dominant negative inhibitory proteins of HIV replication such as the M-10 and those coding
for intrabodies and intrakines can also cause favourable intracellular modifications in the T-
cells making them resistant to HIV infection [148].
Newer studies advocate the combination of both surface and intracellular modifications of the
target cells to obtain improved resilience against HIV [147]. Apart from their role in enhancing
resilience to HIV infection, techniques of genetic manipulation are also useful in conferring
resistance to viral integration and thereby restricting the reservoir formation [155]. Although
the techniques of genetic manipulation has numerous setbacks; poor frequency of recombi‐
nation faced with gene therapy, unwanted off-target effects and double strand break induced
apoptosis occurring with gene editing are the principal challenges that have to be overcome.
Nevertheless, few of these techniques have entered into clinical trials and give hope for a
promising future [152]. Apart from their use in therapeutic strategies, techniques of gene
therapy are being evaluated in DNA vaccines for prophylactic use and also in some of the
strategies of ‘immune therapy’ [156].
6.3. RNA based mechanisms
Studies employing RNA based therapeutics such as antisense oligonucleotides, RNAi,
ribozymes and aptamers have shown to be effective in down-regulation of CCR5 and subse‐
quent inhibition of HIV replication in humanized mice [106, 157]. Of all the above mentioned
technqiues, silencing of CCR5 using RNAi is the most widely studied. RNAi techniques have
also been studied for the downregulation of other cellular factors of HIV replication such as
CXCR4, CD4, NF-κB, LEDGF/p75 and DDX-3 [158].
RNAi techniques for host cell modulation are devoid of the problem of viral escape mutants
that is faced, when the same technique is employed for inhibiting viral targets. However, the
adverse effects faced with these techniqiues are due to loss of other essential functions of the
target cell as a consequence of cellular factor silencing. Increased susceptibility to West Nile
virus infections has been observed with the loss of CCR5 function. CXCR4 downregulation can
disrupt the homeostasis of the lymphopoietic pathway as these receptors are essential for the
homing of stem cells into bone marrow and their subsequent differentiation into T-cells [159].
Novel Prospective Treatment Options
http://dx.doi.org/10.5772/60961
231
Hence, the success of this strategy depends on the identification of suitable cellular co-factors
of HIV infection which can be down regulated without altering the normal cellular physiology.
In the search for such targets, genome wide profiling studies have revealed numerous
previously unknown cellular factors that participate in HIV infection. Subsequent knock down
studies have validated the effectiveness of silencing these factors for limiting HIV replication
[160-162]. Further studies are needed to reveal the adverse effects following the knock down
of these novel cellular factors.
The technique related pitfalls are the same as the ones mentioned earlier, which include the
problems faced with delivery of inhibitory RNAs into specific target cells, off-target effects of
the inhibitory RNAs and cytotoxicity to the administered cell. As of date, only one RNAi
technique has entered clinical trial. The technique was designed to inhibit both viral (tat protein
and TAR RNA) and cellular factors (CCR5). However, the trial was terminated in phase-0 and
the results were not disclosed [163]. Table-5 broadly summarizes all the nucleic acid based
therapeutics that are currently being tried against HIV.
Type Cells targeted Phase acted on Mechanism Technique employed
DNA based
techniques
Infected reservoirs
(In vivo)
Elimination of
latent reservoirs
Direct excision of integrated proviral DNA Genome editing systems -
CRISPR/Cas9, ZFN and
TALEN
Activation of viral replication (Shock and
kill)
Gene therapy - Vectors
based delivery of genes
coding for viral proteins of
replication
Uninfected
susceptible cells
(In vivo / In vitro)
Diversion of natural
course of infection
to make the target
cells resilient
Modification of
normal cellular
components
Cell surface
modifications
Genome editing systems -
CRISPR/Cas9, ZFN and
TALEN to knock out
cellular co-factors that
support HIV replication
Intracellular
modifications
Expression of novel
protective proteins
Cell surface
expression
Gene therapy - Vector
based delivery of cDNA of
novel peptides followed by
their recombination and
expression
Intracellular
expression
RNA based
techniques
Actively infected
cells
(In vivo)
Inhibition of active
viral replication
Inhibition of viral mRNA Agents of RNA interference
(siRNA and shRNA) and to
a lesser extent other RNA
based techniques
(Antisense oligonucleotides,
ribozymes and aptamers)
delivered in viral / non-
viral vectors to the desired
target cells by active
targeting
Inhibition of host cellular factors involved
in viral replication
Uninfected
susceptible cells
(In vivo / In vitro)
Diversion of natural
course of infection
to make the target
cells resilient
Modification of
normal cellular
components
Cell surface
modifications
Intracellular
modifications
Table 5. Nucleic acid based therapeutics for HIV infection
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7. The ‘receptor decoy’ strategy
The receptor decoy strategy is a novel concept which helps to salvage the natural target cells
of HIV by diverting the virus to infect decoy particles, thereby altering the natural course of
HIV infection. This involves the usage of decoy cells termed ‘cancellers‘, which possess HIV
entry receptors on their surface and do not contain the machinery required for retro-viral
replication. The cancellers (Figure-2) intend to function as decoys and get infected by the free
HIV virions thereby preventing the infection of the natural target cells. Apart from protection
of the natural target cells, the cancellers also serve to limit viremia as the trapped virions cannot
replicate inside the cancellers due to the absence of replication machinery. Optionally, the
trapped virions could be destroyed by packing anti-viral agents within the cancellers [164].
Figure 2. Schematic representation of a canceller particle. RBC particle reconstituted with receptors on the membrane
surface and loaded with various molecules. CD4 (red) and CCR5 (green) receptors are involved in the active targeting
of HIV virions. Accessory surface molecules (orange) may be added to enhance the fusion process and/or to prevent
elimination of the canceller by reticulo-endothelial system. Molecules capable of viral destruction (blue spheres and
yellow stars) such as protein and RNA damaging agents are packed within the canceller.
The superiority of the receptor decoy strategy over the conventional anti-retroviral drugs is
that it mimics natural conditions and is thereby devoid of the ‘adverse factor’ effect in selecting
out resistance. This attractive strategy is in the concept phase and more discussions and
comments could be made only after its implementation. Similar strategies employing modified
erythrocytes or nanoparticles as viral traps are being studied for their use against HIV [164].
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8. Immune based therapies
Since the discovery of HIV repeated attempts to achieve effective protection using conven‐
tional methods of immunoprophylaxis have resulted in outright failure. The failure of the
preventive strategies has lead to the concept of ‘immunotherapy’ or ‘immune based therapy’.
This strategy involves in the manipulation of the immune system in a therapeutic motive to
eliminate the already acquired infection, rather than preventing new infection. The immune
based therapies involve in enhancing the potency of the immune system to counteract HIV by
reducing inflammation, preventing immune activation by HIV-1 or promoting effective
immune responses against HIV. The different modalities used to achieve this effect can be
broadly classified into non-HIV antigen specific therapies and those which use the HIV
antigens (Table-6)[6, 165].
None of the immune based therapies have provided satisfactory results so far. Among the
available methods of immunotherapy, HIV specific CTL induction using the dendritic cells is
of recent interest and appears to be a promising strategy. Recent studies reveal that a thera‐
peutic vaccine using autologous monocyte-derived dendritic cells pulsed with heat-inactivat‐
ed whole HIV, stimulated anti-HIV immune response and shifted the virus/host balance in
favor of the host when administered to patients on HAART with CD4+ T-cell count >450 cells/
mm. At week 12 after ART interruption, 55% of people in the vaccinated group represented
decrease of their viral load by at least 10-fold or 90%, compared with just 9% in the control
group receiving non-pulsed DCs. These proportions dropped to 35% and 0%, respectively at
week 24. This significant decrease in plasma viral load observed in vaccinated recipients was
associated with a consistent increase in HIV-1-specific T cell responses. These data indicate
that HIV-1-specific immune responses are elicited by the therapeutic DC vaccination. This
could significantly reduce plasma viremia after ART interruption in HIV patients chronically
infected but controlled with sufficiently high CD4 numbers. Thus, this study warrants further
investigation with new candidates and/or new optimized strategies of vaccination toward the
final goal to achieve a functional cure of HIV infection. Although heat-inactivated whole HIV
was used as the antigen in this strategy, direct expression of the mRNA derived from patient's
cells can also be considered using DCs in the immune therapy which expects highly precise
antiviral efficacy targeting not only HIV but also non-viral antigens [166].
9. Complementary and alternative therapies
It is a common feature that people living with HIV or AIDS across the world resort to products
and practices that are not presently considered to be part of conventional anti-retroviral
medicine. When these are used together with conventional anti-retroviral medications, they
are referred to as complementary therapies and if used as a stand-alone modality instead of
conventional medications, they are referred to as alternative therapies [167]. A plethora of
complementary and alternative strategies are available from all over the world which pre‐
dominantly involves the use of natural products and/or mind and body practices. Herbal
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Types Components Examples Mechanism
Non-antigen
specific
therapies
Cytokines Interleukin-2
(Proleukin)
Augmentation of CD4 T-cell proliferation and cytolytic
function of CD8 T-cells
Interleukin-7 Improvement of T-cell homeostasis
Interleukin-12 Enhancement of Th1 response and increasing the cytotoxic
activity of T-cells and NK cells against virally infected cells
Interleukin-15 Expansion of effector and memory subsets of CD* T-cells
Interleukin-21 Proliferation and enhancement of the cytolytic potential of
effector CD8 T-cells
Drugs Chloroquine Reduction of IFN-α in order to reduce the immune activation
to prevent depletion of CD4 T-cells and progression to AIDSHydroxy
chloroquine
Aspirin Reduction of T-cell activation due to its broad anti-
inflammatory property
Celecoxib Inhibition of cyclo-oxygenase type-2 enzyme to reduce T-cell
activation
Antibodies Anti-CD4
(Ibalizumab)
Competitive inhibition of viral entry receptors
Anti-CCR5 Competitive inhibition of viral entry receptors
Anti-PD-1 Blockage of the negative co-stimulatory molecules PD-1 and
CLTA4 on the surface of T-cells to prevent CD8 T-cell
dysfunction and enhancement of CD4 T-cell proliferation
Anti-CLTA4
Prebiotics and probiotics Modulation of the gut microbiome and amelioration of HIV
induced mucosal damage
Antigen
specific
therapies
Vaccines Inactivated whole
virus
gp120 depleted, inactivated HIV strain with incomplete
Freund's adjuvant
Antigenic sub-units
of HIV
Recombinant immunodominant proteins of HIV with suitable
adjuvants
Viral vectors
expressing HIV
antigens
Various HIV specific antigens expressed on different viral
vectors
DNA Plasmids containing one or more genetic determinants coding
for HIV proteins
Dendritic cell Delivery of viral antigens to dendritic cells to ensure activation
of both CD4 and CD8 T-cells
Table 6. Immune based therapies being developed against HIV
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remedies derived from the ancient medical science forms of different countries are the most
widely sought after modality of complementary or alternative therapies. The various mind
and body techniques include spirituality, meditation, yoga and other body manipulatory
procedures, acupuncture and energy therapies [168].
Observations across the globe reveal that 30 - 90% of the HIV infected patients seek for
complementary or alternative therapies of which, majority are females and educated individ‐
uals [169, 170]. The usefulness of these therapies is controversial. Spiritual methods such as
prayer, faith healing and meditation are found to improve the psychological state by helping
to overcome anxiety, depression and stress thereby providing a feeling of well being [171]. The
compound IGM-1, obtained from herbs used in traditional medicine was observed to alleviate
the symptoms of HIV infection but did not have any effect in reduction of viremia or improving
the immune status. Many of the other Chinese herbal medicines tested were found to be
unsatisfactory in altering the viral and immune parameters [172]. To much despair, several
studies have highlighted the deleterious effects of complementary and alternative medicines.
Recent reports indicate that patients on concurrent complementary therapy have reduced
adherence rate to conventional anti-retroviral therapeutic regimens [173]. Homeopathy, a
traditional health system has been proven ineffective for the treatment of HIV infection and
has been disregarded by the WHO [174]. Herbal preparations containing St. John’s Wort and
those containing garlic extracts reduce the therapeutic levels of conventional anti-retrovirals.
Apart from reducing the efficacy, many other herbal preparations have also been observed to
increase the HAART related side effects [169].
Despite these assumptions, complementary and alternative therapies cannot be totally
overlooked. This is due to the fact that natural compounds with antiretroviral property such
as indirubin monoxime and tanshinone II A have been isolated from herbal medications [80,
81]. Meta analyses on the efficacy of herbal preparations have yielded only inconclusive results
but not ineffective [172, 175]. Hence rigorous clinical trials including large study population
are required to refute or accept the potential benefits of these therapeutic modalities. National
Centre for Complementary and Alternative medicine, a division of the National Institute of
Health, USA is an organization dedicated for research in alternative and complementary
medicines and thus provides funding to various studies in this field [167].
10. Conclusions
The HAART has played its crucial role in curtailing the HIV pandemic so far. However, its
inability to eliminate the infection and the rise of resistant mutants is a fundamental challenge.
This has initiated the frantic search for novel compounds and strategies to counteract HIV.
Desperate measures have resulted in the discovery of a plethora of anti-retroviral compounds
and strategies, but none could be unanimously agreed upon as completely reliable. The much
hyped functional cure concept has taken a big blow with the occurrence of rebound viremia
in the Mississippi baby. Moreso, studies to replicate the sterilizing cure of the Berlin patient
have provided disappointing results. Despite the development of various novel antiviral
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compounds, HIV is well set before-hand to readily evolve and overcome all anti-viral actions.
Novel techniques such as gene therapy, gene editing, RNA interference, anti-retroviral
peptides may have sound concepts and appear attractive but in reality they face numerous
roadblocks. By virtue of the ability to undergo rapid genetic evolution and the tendency to
establish latent reservoirs, HIV has thwarted all the overcoming attempts. Currently, efforts
are being stepped-up by scientist globally to overcome the challenges discussed herein, though
the strategy(ies) may face limitations today but they still have the potential to achieve the
required success of sustained functional cure.
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